A human test is going to be conducted to test the effect of the Kovid-19 vaccine on pregnant women. On Thursday, drug maker Pfizer and BioNotech announced in this regard. For this, 4 thousand healthy volunteers will be included. Doctor William Gruber, senior vice president of Pfizer’s clinical research and development department, told in an interview that the results of human trials could be released by the fourth quarter of 2021.
Kovid-19 vaccine to be tested on pregnant women
He said that the data has so far indicated that pregnant women suffering from Kovid-19 have a higher severity rate. They also have to do more than the complication of pregnancy such as premature birth, healthy pregnant women. Human trials will explore the effects of the vaccine on pregnant women aged 18 or older in the US, Canada, Brazil, Chile, Argentina, South Africa, Britain and Spain.
Women will be administered two doses of vaccine in the 24–34 week of pregnancy, leaving 21 days. On behalf of the pharmaceutical companies, it was said that shortly after giving birth, Volunteer in the placebo group will get the actual vaccine. During human testing, it will also be checked whether pregnant women using the vaccine transfer antibodies to their children from the virus.
Pfizer and BioNtech to test the impact of their vaccine
Drug manufacturer companies say they first need to ensure that vaccines are generally more safe and effective. Health experts have advocated the inclusion of pregnant women at the beginning of human trials for the epidemic vaccine. They argue that after the successful vaccine, women will not have to wait for long.
Pharmaceutical manufacturers are required to test for safety on pregnant animals before testing the vaccine on pregnant women. So that the vaccine should not harm the fetus or there is a risk of miscarriage. Pharmaceutical companies have said that those research has revealed that there is no new threat.
Avian H5N8 Flu in Humans: Bird flu virus in humans, seven people infected with poultry farm in Russia
Study reveals, Oxford vaccine dose of three months interval is more effective than 6 week gap